A SAM domain network in Polycystic Kidney Disease

多囊肾病中的 SAM 域网络

基本信息

  • 批准号:
    9205230
  • 负责人:
  • 金额:
    $ 28.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-01-01 至 2018-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Polycystic kidney disease (PKD) is one of the most common lethal genetic diseases. Mutations in the Sterile Alpha Motif (SAM) domains of Bicaudal-C (Bicc1) and Samcystin/Anks6 are known to cause cystic disease in humans, rats or mice by unknown mechanisms. Prior work, and our own preliminary results, have established an interaction network between the SAM domains of Bicc1, Anks6 and a new protein we have identified called Anks3. Bicc1 regulates cell polarity and the expression of several proteins known to contribute to PKD. The fact that both Anks3 and Anks6 bind to the key regulatory protein Bicc1, suggests that they may be important for Bicc1 function. We propose to test two primary hypotheses: (1) That Anks6 and Anks3 can modulate the functions of Bicc1 either separately or together via there SAM domain interactions. (2) That the newly identified Anks3 protein can modulate the development of PKD. Aim 1. We will physically and structurally characterize the SAM mediated interactions of Bicc1, Ank3 and Anks6. An understanding of the architecture of the complexes will be important for understanding the biological consequences of SAM domain mutations. Aim 2. Test the hypothesis that Anks3 and Anks6 modulate known Bicc1 functions in cellular assays. We will examine the effects of Anks3 an Anks6 on cellular localization of Bicc1, protein expression and Wnt signaling. Aim 3. Test the hypothesis that Anks3 mutations can generate PKD in transgenic rats. Transgenic rat strains will be created where Anks3 is over-expressed or deleted and examined for the development of cystic disease. We will also study how these alterations affect the development of PKD in Anks6 mutant rats. The project has the potential to explain the mechanism of several disease-causing mutations, identify functions of proteins involved in PKD, and identify a new player in the complex pathway to PKD.
描述(由申请人提供):多囊肾病(PKD)是最常见的致死性遗传疾病之一。已知Bicc 1和Samcystin/Anks 6的无菌α基序(SAM)结构域的突变会通过未知机制引起人类、大鼠或小鼠的囊性疾病。先前的工作,以及我们自己的初步结果,已经建立了Bicc 1,Anks 6的SAM结构域和我们已经确定的称为Anks 3的新蛋白质之间的相互作用网络。Bicc 1调节细胞极性和已知有助于PKD的几种蛋白质的表达。Anks 3和Anks 6都与关键调节蛋白Bicc 1结合,这表明它们可能对Bicc 1功能很重要。我们提出了两个主要假设:(1)Anks 6和Anks 3可以通过SAM结构域相互作用单独或共同调节Bicc 1的功能。(2)新发现的Anks 3蛋白对PKD的发生、发展有调节作用。目标1。我们将在物理和结构上表征SAM介导的Bicc 1,Ank 3和Anks 6的相互作用。理解的结构的复合物将是重要的理解SAM结构域突变的生物学后果。目标2.检验Anks 3和Anks 6在细胞测定中调节已知Bicc 1功能的假设。我们将研究Anks 3和Anks 6对Bicc 1细胞定位、蛋白表达和Wnt信号传导的影响。目标3。测试Anks 3突变可以在转基因大鼠中产生PKD的假设。将创建Anks 3过表达或缺失的转基因大鼠品系,并检查囊性疾病的发展。我们还将研究这些改变如何影响Anks 6突变大鼠PKD的发展。该项目有可能解释几种致病突变的机制,确定参与PKD的蛋白质的功能,并确定PKD复杂途径中的新参与者。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
ANKS3 Co-Localises with ANKS6 in Mouse Renal Cilia and Is Associated with Vasopressin Signaling and Apoptosis In Vivo in Mice.
ANKS3在小鼠肾纤毛中与ANKS6共定位,并与小鼠体内的加压素信号传导和凋亡相关。
  • DOI:
    10.1371/journal.pone.0136781
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Delestré L;Bakey Z;Prado C;Hoffmann S;Bihoreau MT;Lelongt B;Gauguier D
  • 通讯作者:
    Gauguier D
CTGF Is Expressed During Cystic Remodeling in the PKD/Mhm (cy/+) Rat Model for Autosomal-Dominant Polycystic Kidney Disease (ADPKD).
CTGF 在常染色体显性多囊肾病 (ADPKD) PKD/Mhm (cy/ ) 大鼠模型的囊性重塑过程中表达。
Exome sequencing and CRISPR/Cas genome editing identify mutations of ZAK as a cause of limb defects in humans and mice.
  • DOI:
    10.1101/gr.199430.115
  • 发表时间:
    2016-02
  • 期刊:
  • 影响因子:
    7
  • 作者:
    Spielmann M;Kakar N;Tayebi N;Leettola C;Nürnberg G;Sowada N;Lupiáñez DG;Harabula I;Flöttmann R;Horn D;Chan WL;Wittler L;Yilmaz R;Altmüller J;Thiele H;van Bokhoven H;Schwartz CE;Nürnberg P;Bowie JU;Ahmad J;Kubisch C;Mundlos S;Borck G
  • 通讯作者:
    Borck G
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES U BOWIE其他文献

JAMES U BOWIE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES U BOWIE', 18)}}的其他基金

A SAM domain network in Polycystic Kidney Disease
多囊肾病中的 SAM 域网络
  • 批准号:
    8613279
  • 财政年份:
    2014
  • 资助金额:
    $ 28.14万
  • 项目类别:
Membrane Protein Folding
膜蛋白折叠
  • 批准号:
    8529131
  • 财政年份:
    2013
  • 资助金额:
    $ 28.14万
  • 项目类别:
The 27th Annual Symposium of The Protein Society
第27届蛋白质学会年会
  • 批准号:
    8597253
  • 财政年份:
    2013
  • 资助金额:
    $ 28.14万
  • 项目类别:
2011 Proteins
2011 蛋白质
  • 批准号:
    8128057
  • 财政年份:
    2011
  • 资助金额:
    $ 28.14万
  • 项目类别:
SAM Domains
SAM 域
  • 批准号:
    8245084
  • 财政年份:
    2010
  • 资助金额:
    $ 28.14万
  • 项目类别:
SAM Domains
SAM 域
  • 批准号:
    8053724
  • 财政年份:
    2010
  • 资助金额:
    $ 28.14万
  • 项目类别:
SAM Domains
SAM 域
  • 批准号:
    7906978
  • 财政年份:
    2010
  • 资助金额:
    $ 28.14万
  • 项目类别:
Bridge 6: H-bond Dynamics and Alpha-Helix Conformational Flexibility
桥梁 6:氢键动力学和 α-螺旋构象灵活性
  • 批准号:
    9149310
  • 财政年份:
    2010
  • 资助金额:
    $ 28.14万
  • 项目类别:
Formulatrix Automated Protein Crystallization System
Formulatrix 自动化蛋白质结晶系统
  • 批准号:
    7214401
  • 财政年份:
    2007
  • 资助金额:
    $ 28.14万
  • 项目类别:
Improving membrane protein crystallization
改善膜蛋白结晶
  • 批准号:
    7493752
  • 财政年份:
    2007
  • 资助金额:
    $ 28.14万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.14万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了